Segment & Geographic Data
Quant-Grade Normalized (live API)
API & CSV Delivery
International Stem Cell's Business Segments
International Stem Cell's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.
Segment Data As of Q1 FY2026
Reportable Segments
3
Largest Segment
Biomedical Market
Total Revenue
$ 2
Regions Reported
-
Revenue Share by Reportable Segment - Q1 FY2026
- Biomedical Market93.7%
- Anti Aging Market6.3%
- Anti Aging Skincare Market6.3%
Revenue by Reportable Segment - Q1 FY2026
| Segment | Revenue (Millions) | % of Total |
|---|---|---|
| Biomedical Market | $ 2 | 93.7% |
| Anti Aging Market | $ 0 | 6.3% |
| Anti Aging Skincare Market | $ 0 | 6.3% |
Revenue by Product & Service Category - Q1 FY2026
- Media57%
- Cells36.8%
Revenue by Product & Service Category - Q1 FY2026
| Category | Revenue (Millions) | % of Total |
|---|---|---|
| Media | $ 1 | 57% |
| Cells | $ 1 | 36.8% |
Product and service categories are a supplemental disclosure and are not required to sum to consolidated revenue or to the reportable segments above.
Description of International Stem Cell
International Stem Cell Corporation (ISCO) is a publicly traded biotechnology company that specializes in the development and commercialization of therapeutic and research products derived from human stem cells. The company was founded in 2001 and is headquartered in Carlsbad, California, with additional facilities in Oceanside, California and Warsaw, Poland.
ISCO is differentiated by its proprietary technology platform called parthenogenesis, which enables the creation of human pluripotent stem cells (hPSCs) without the need for fertilized embryos. This approach overcomes ethical concerns surrounding the use of embryonic stem cells and allows the company to produce a diverse range of cell types that can be used for the treatment of various diseases and conditions.
ISCO's product pipeline is focused on three main areas: therapeutic development, a stem cell bank, and gene therapies. In the therapeutic development segment, the company is actively developing treatments for a range of medical conditions, including Parkinson's disease, liver disease, and corneal blindness. ISCO's stem cell bank offers access to a range of human stem cell lines for research purposes, facilitating scientific advancements in the field. Additionally, the company is exploring the potential of gene therapies to treat genetic disorders.
The company's flagship product is a treatment for Parkinson's disease called ISC-hpNSC®, which involves the transplantation of neural stem cells into the brain. ISCO has completed Phase I clinical trials for this therapy and is currently conducting Phase II trials in Australia. The treatment aims to replace the dopamine-producing neurons that are lost in patients with Parkinson's disease, potentially offering a long-term solution to the debilitating symptoms of the condition.
In addition to its therapeutic development efforts, ISCO is actively engaged in research collaborations with academic institutions and other biotechnology companies. The company has formed partnerships with organizations such as the University of California, San Diego, and the Coriell Institute for Medical Research to advance its research and development goals.
ISCO's business model also includes licensing and sublicensing its technology and products to other companies. This strategy allows the company to expand its reach and likely generate additional revenue streams through royalties and milestone payments.
As a publicly traded company, ISCO is subject to regulatory oversight and financial reporting requirements. Its stock is traded on the NASDAQ exchange under the ticker symbol ISCO.
In conclusion, International Stem Cell Corporation is a leading biotechnology company that is at the forefront of stem cell research and development. With its proprietary parthenogenesis technology and diverse product pipeline, the company is positioned to make significant contributions to the field of regenerative medicine and is dedicated to improving the lives of patients globally.
ISCO is differentiated by its proprietary technology platform called parthenogenesis, which enables the creation of human pluripotent stem cells (hPSCs) without the need for fertilized embryos. This approach overcomes ethical concerns surrounding the use of embryonic stem cells and allows the company to produce a diverse range of cell types that can be used for the treatment of various diseases and conditions.
ISCO's product pipeline is focused on three main areas: therapeutic development, a stem cell bank, and gene therapies. In the therapeutic development segment, the company is actively developing treatments for a range of medical conditions, including Parkinson's disease, liver disease, and corneal blindness. ISCO's stem cell bank offers access to a range of human stem cell lines for research purposes, facilitating scientific advancements in the field. Additionally, the company is exploring the potential of gene therapies to treat genetic disorders.
The company's flagship product is a treatment for Parkinson's disease called ISC-hpNSC®, which involves the transplantation of neural stem cells into the brain. ISCO has completed Phase I clinical trials for this therapy and is currently conducting Phase II trials in Australia. The treatment aims to replace the dopamine-producing neurons that are lost in patients with Parkinson's disease, potentially offering a long-term solution to the debilitating symptoms of the condition.
In addition to its therapeutic development efforts, ISCO is actively engaged in research collaborations with academic institutions and other biotechnology companies. The company has formed partnerships with organizations such as the University of California, San Diego, and the Coriell Institute for Medical Research to advance its research and development goals.
ISCO's business model also includes licensing and sublicensing its technology and products to other companies. This strategy allows the company to expand its reach and likely generate additional revenue streams through royalties and milestone payments.
As a publicly traded company, ISCO is subject to regulatory oversight and financial reporting requirements. Its stock is traded on the NASDAQ exchange under the ticker symbol ISCO.
In conclusion, International Stem Cell Corporation is a leading biotechnology company that is at the forefront of stem cell research and development. With its proprietary parthenogenesis technology and diverse product pipeline, the company is positioned to make significant contributions to the field of regenerative medicine and is dedicated to improving the lives of patients globally.
International Stem Cell Corporation (ISCO) is a biotechnology company focused on groundbreaking research and development involving human stem cells. The companys mission is to create innovative therapies and products through ethical stem cell technology. Below is a comprehensive description of the segments, products, and services that ISCO offers.
Segments
1. Therapeutics:
- Cell Therapy: ISCO is particularly focused on the use of stem cells for regenerative medicine. The company is developing stem cell-derived therapies targeting various conditions, including neurodegenerative diseases, spinal cord injuries, and metabolic disorders. The versatility of stem cells allows for the potential treatment of a wide array of diseases.
2. Research and Development:
- This segment encompasses the fundamental research necessary to explore the potential of stem cells in various applications, including drug discovery, toxicity testing, and disease modeling. ISCO invests in R&D to advance its understanding and application of stem cells.
3. Biotechnology Products:
- ISCO produces and markets human-derived stem cell lines and related products. These products are intended for research purposes, such as studying human disease mechanisms, drug efficacy, and the development of personalized medicine.
4. Regenerative Medicine Research:
- The company conducts extensive research aimed at leveraging stem cells for the repair or regeneration of damaged tissues and organs. This segment is key to developing therapies that may one day address currently untreatable conditions.
Products
1. Stem Cell Lines:
- ISCO develops and sells ethically derived human stem cell lines. These stem cell lines are crucial for researchers in both academia and industry who are investigating cell therapies or drug testing. The availability of these lines facilitates the advancement of scientific knowledge and therapeutic applications.
2. Cell-based Products:
- The company is involved in the development of cell-based products that can be used in a variety of applications, from research to potential therapeutic solutions. These products are primarily composed of differentiated cells derived from stem cells.
3. Research Tools and Kits:
- ISCO offers various research tools and kits designed for scientists working in stem cell research. These products may include reagents, culture media, and other necessary materials to help support experiments involving stem cells.
4. Therapeutic Platforms:
- Beyond specific products, ISCO is developing therapeutic platforms aimed at specific disease areas. These platforms may involve unique formulations or delivery methods of stem cell therapies that can be tailored to treat specific conditions.
Services
1. Contract Research Services:
- ISCO provides contract research services to companies and institutions in need of assistance with stem cell-related research. This may include collaboration for drug discovery, toxicology studies, and preclinical testing of therapeutic candidates.
2. Custom Stem Cell Research Solutions:
- The company offers tailored research services, including the customization of stem cell lines or protocols that suit specific research needs. This service is aimed at providing researchers with the exact resources they require for their specific projects.
3. Consulting Services:
- ISCO provides consulting services to organizations looking to navigate the complexities of stem cell research and therapy development. This may include guidance on regulatory compliance, clinical trial design, and market strategies.
4. Collaborative Research Agreements:
- The company actively engages in partnerships and collaborations with academic institutions and other companies. These agreements often involve shared research initiatives to accelerate the development of novel therapies.
5. Training and Education:
- ISCO is committed to educating the scientific community about the potential of stem cell technology and its applications. This may involve workshops, seminars, and training programs focused on the best practices in stem cell research.
Summary
International Stem Cell Corporation is at the forefront of stem cell research and application, offering a wide range of products, services, and segments focused on harnessing the potential of stem cells. From therapeutic developments to research tools, ISCO’s commitment to innovative solutions aims to address some of the most pressing medical challenges facing society today. Through its extensive portfolio, ISCO is positioned to be a key player in the biotechnology and regenerative medicine fields.
Segments
1. Therapeutics:
- Cell Therapy: ISCO is particularly focused on the use of stem cells for regenerative medicine. The company is developing stem cell-derived therapies targeting various conditions, including neurodegenerative diseases, spinal cord injuries, and metabolic disorders. The versatility of stem cells allows for the potential treatment of a wide array of diseases.
2. Research and Development:
- This segment encompasses the fundamental research necessary to explore the potential of stem cells in various applications, including drug discovery, toxicity testing, and disease modeling. ISCO invests in R&D to advance its understanding and application of stem cells.
3. Biotechnology Products:
- ISCO produces and markets human-derived stem cell lines and related products. These products are intended for research purposes, such as studying human disease mechanisms, drug efficacy, and the development of personalized medicine.
4. Regenerative Medicine Research:
- The company conducts extensive research aimed at leveraging stem cells for the repair or regeneration of damaged tissues and organs. This segment is key to developing therapies that may one day address currently untreatable conditions.
Products
1. Stem Cell Lines:
- ISCO develops and sells ethically derived human stem cell lines. These stem cell lines are crucial for researchers in both academia and industry who are investigating cell therapies or drug testing. The availability of these lines facilitates the advancement of scientific knowledge and therapeutic applications.
2. Cell-based Products:
- The company is involved in the development of cell-based products that can be used in a variety of applications, from research to potential therapeutic solutions. These products are primarily composed of differentiated cells derived from stem cells.
3. Research Tools and Kits:
- ISCO offers various research tools and kits designed for scientists working in stem cell research. These products may include reagents, culture media, and other necessary materials to help support experiments involving stem cells.
4. Therapeutic Platforms:
- Beyond specific products, ISCO is developing therapeutic platforms aimed at specific disease areas. These platforms may involve unique formulations or delivery methods of stem cell therapies that can be tailored to treat specific conditions.
Services
1. Contract Research Services:
- ISCO provides contract research services to companies and institutions in need of assistance with stem cell-related research. This may include collaboration for drug discovery, toxicology studies, and preclinical testing of therapeutic candidates.
2. Custom Stem Cell Research Solutions:
- The company offers tailored research services, including the customization of stem cell lines or protocols that suit specific research needs. This service is aimed at providing researchers with the exact resources they require for their specific projects.
3. Consulting Services:
- ISCO provides consulting services to organizations looking to navigate the complexities of stem cell research and therapy development. This may include guidance on regulatory compliance, clinical trial design, and market strategies.
4. Collaborative Research Agreements:
- The company actively engages in partnerships and collaborations with academic institutions and other companies. These agreements often involve shared research initiatives to accelerate the development of novel therapies.
5. Training and Education:
- ISCO is committed to educating the scientific community about the potential of stem cell technology and its applications. This may involve workshops, seminars, and training programs focused on the best practices in stem cell research.
Summary
International Stem Cell Corporation is at the forefront of stem cell research and application, offering a wide range of products, services, and segments focused on harnessing the potential of stem cells. From therapeutic developments to research tools, ISCO’s commitment to innovative solutions aims to address some of the most pressing medical challenges facing society today. Through its extensive portfolio, ISCO is positioned to be a key player in the biotechnology and regenerative medicine fields.